Invivyd Completes Enrollment in Pivotal VYD2311 Trial, Setting Up Late Q3 2026 Data Readout

What happened

Invivyd announced completion of enrollment in its upsized Phase 3 DECLARATION trial evaluating VYD2311 for COVID-19 prevention, with top-line results expected in late Q3 2026. The BLA-enabling study targets a broad population including adults and adolescents, moving the next-generation antibody closer to potential regulatory submission. However, the company's recent commercial execution has been materially underwhelming, with 2024 PEMGARDA revenue of ~$25M far below the initial $150–$200M target. Variant susceptibility thresholds and IV infusion logistics continue to gate utilization, while AstraZeneca's sipavibart poses imminent competitive pressure. The trial completion reduces one uncertainty but does not resolve the core challenges of commercial adoption and variant escape risk.

Implication

The enrollment milestone is a positive operational step but does not alter the fundamental thesis: Invivyd must demonstrate durable variant susceptibility, a credible commercial ramp, and competitive differentiation against sipavibart. The master report's HOLD rating remains appropriate given balanced risk/reward, with the VYD2311 data readout as the next major catalyst. Upside depends on superior efficacy, convenient dosing (IM/SC), or a clear immunobridging path that outpaces rivals. Downside scenarios include variant escape rendering VYD2311 ineffective, or sipavibart securing a broad label before Invivyd can commercialize. Until top-line results are reported, the stock will likely trade on EUA updates for PEMGARDA and quarterly revenue trends, which remain sub-scale.

Thesis delta

The completion of DECLARATION enrollment does not shift the core thesis; it merely crystallizes a key catalyst timeframe. The thesis remains HOLD pending proof of commercial execution and variant resilience, with the data readout now the primary determinant of a potential upgrade (if positive and differentiated) or downgrade (if negative or uncompetitive).